Novo Nordisk (NOVA) Price & Analysis
NOVA Stock Chart & Stats
- Day’s Range
- EUR 34.62 - EUR 35.64
- 52-Week Range
- EUR 30.45 - EUR 54.80
- Previous Close
- EUR 34.68
- Volume
- 50
- Average Volume (3M)
- 992
- Market Cap
- EUR 157.17B
- Enterprise Value
- EUR 227.20B
- Total Cash (Recent Filing)
- EUR 44.98B
- Total Debt (Recent Filing)
- EUR 140.13B
- Price to Earnings (P/E)
- 10.1
- Beta
- 0.70
- Next Earnings
- Nov 04, 2026
- EPS Estimate
- 0.65
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 4.33%
Bulls Say, Bears Say
Bulls Say
Exceptional Growth And Profitability
Novo combines rapid revenue expansion with unusually high profitability, indicating strong product economics and pricing power in chronic-care medicines. These margins can support substantial reinvestment in manufacturing, commercial expansion and research while providing resilience through normal business-cycle fluctuations.
Leading GLP-1 Market Position
The strong position across injectable and oral obesity treatments demonstrates substantial commercial execution, brand strength and patient adoption. Oral-market leadership also broadens the addressable market and may help Novo retain relevance as treatment preferences evolve and obesity care expands internationally.
Pipeline And Licensing Expansion
The HRS-1596 license adds a potential once-weekly oral therapy to Novo’s obesity pipeline and strengthens access to next-generation mechanisms. Although development remains uncertain, the deal broadens future product options and supports ongoing innovation beyond the current semaglutide franchise.
Bears Say
Challenging 2026 Outlook
Management’s flat-to-declining 2026 outlook signals that near-term growth is being pressured by lower realized prices, competition, coverage reductions and semaglutide exclusivity losses. These forces could persist across the next several quarters and make recent exceptional growth harder to sustain.
Higher Leverage And Weaker Cash Conversion
The sharp increase in borrowing reduces financial flexibility relative to the company’s earlier balance-sheet position, while weak free-cash-flow conversion limits the cash cushion behind reported earnings. Continued investment and capital returns will therefore require closer discipline if product conditions soften.
Clinical Pipeline Setback
ZEUS weakens the potential contribution of ziltivekimab and highlights the uncertainty of Novo’s expansion into higher-risk disease areas. The result may also increase reliance on obesity and diabetes programs, making successful development and commercialization of replacement pipeline assets more important.
Novo Nordisk News
Novo Nordisk Advances Mim8 Trial in Rare Haemophilia A, Expanding Its Specialty Pipeline
Novo Nordisk ($NVO) announced an update on their ongoing clinical study. The study “A Multinational, Open-label Study to Investigate Efficacy and Safety of Denecimig (Mim8) in Adults With Acquired Haemophilia
NOVA FAQ
What was Novo Nordisk’s price range in the past 12 months?
What is Novo Nordisk’s market cap?
When is Novo Nordisk’s upcoming earnings report date?
How were Novo Nordisk’s earnings last quarter?
Is Novo Nordisk overvalued?
Does Novo Nordisk pay dividends?
What is Novo Nordisk’s EPS estimate?
How many shares outstanding does Novo Nordisk have?
What happened to Novo Nordisk’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Novo Nordisk?
What is the TipRanks Smart Score and how is it calculated?
Novo Nordisk Stock Smart Score
Company Description
Novo Nordisk
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar
- Employees
- 68,794
- Website
- www.novonordisk.com
- Address
- Novo Alle 1, Bagsvaerd, CR, 2880, DK
Novo Nordisk (NOVA) Earnings & Revenues
NOVA Company Deck
NOVA Earnings Call
Earnings Call SentimentPositive
The call was broadly constructive, supported by strong GLP-1 volume growth, rapid Wegovy pill uptake in the U.S. and international markets, continued pipeline advancement, Q2 sales growth of 7%, operating profit growth of 11%, and transformation savings ahead of plan. However, the company faces material headwinds from lower realized prices, declining gross margin, U.S. competition and coverage pressure, semaglutide loss of exclusivity, declining international market share, and the unsuccessful ZEUS cardiovascular outcomes trial. Overall, the highlights significantly outweigh the lowlights, although management characterized 2026 as a challenging year.
View all DE:NOVA earnings summariesNOVA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 4 | 8 |
| Technical Analysis | 3 | 4 | 2 |
| Moving Averages | 6 | 0 | 6 |